<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702425</url>
  </required_header>
  <id_info>
    <org_study_id>CVOB560A12101</org_study_id>
    <nct_id>NCT04702425</nct_id>
  </id_info>
  <brief_title>VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)</brief_title>
  <official_title>A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be&#xD;
      safely given and to learn if the combination can have possible benefits for patients with&#xD;
      Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).&#xD;
&#xD;
      VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2&#xD;
      (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect&#xD;
      tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions&#xD;
      of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo&#xD;
      cell death.&#xD;
&#xD;
      Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665&#xD;
      induces robust anti-tumor activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">January 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs, including changes in lab values, vital signs, and ECGs</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs) during the first cycle of treatment with VOB560 and MIK665 in combination</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate (and rate of CR or sCR in R/R MM)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>at month 18</time_frame>
    <description>Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of VOB560</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) ok VOB560</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2) of VOB560</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of VOB560</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz) of VOB560</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of MIK665</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) ok MIK665</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2) of MIK665</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of MIK665</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz) of MIK665</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>PK parameter</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Non-Hodgkin Lymphoma (NHL)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Multiple Myeloma (MM)</condition>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VOB560-MIK665 - Part 2d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VOB560</intervention_name>
    <description>Powder for concentrate for solution for infusion</description>
    <arm_group_label>VOB560-MIK665 - Part 1a</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 1b</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2a</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2b</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2c</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2d</arm_group_label>
    <other_name>S65487</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIK665</intervention_name>
    <description>Concentrate for solution for infusion</description>
    <arm_group_label>VOB560-MIK665 - Part 1a</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 1b</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2a</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2b</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2c</arm_group_label>
    <arm_group_label>VOB560-MIK665 - Part 2d</arm_group_label>
    <other_name>S64315</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of one of the following hematologic malignancies:&#xD;
&#xD;
               -  relapsed and/or refractory patients with non-Hodgkin lymphoma with&#xD;
                  radiographically measurable disease with a clearly demarcated nodal lesion at&#xD;
                  least 1.5 cm in its largest dimension or a target extra nodal lesion at least 1.0&#xD;
                  cm in its largest dimension&#xD;
&#xD;
               -  relapsed and/or refractory patients with MM treated with at least 2 prior&#xD;
                  regimens, including an IMiD, a proteasome inhibitor proteasome inhibitor, and&#xD;
                  anti-CD38 antibody (if available) and not eligible for treatment with other&#xD;
                  regimens known to provide clinical benefit, as determined by the investigator.&#xD;
&#xD;
               -  relapsed and/or refractory patients with Acute Myeloid Leukemia (AML),&#xD;
                  pathologically confirmed diagnosis as defined by the WHO Classification and with&#xD;
                  ≥ 5% blasts in bone marrow. Following ≥ 1 prior therapies who have relapsed or&#xD;
                  exhibited refractory disease (primary failure) and are deemed by the investigator&#xD;
                  not to be candidates for standard therapy, including re-induction with cytarabine&#xD;
                  or other established therapeutic regimens for patients with AML (patients who are&#xD;
                  suitable for standard re-induction chemotherapy or hematopoietic stem cell&#xD;
                  transplantation and willing to receive it are excluded).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.&#xD;
&#xD;
          -  Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to&#xD;
             the institution's guidelines and be willing to undergo a bone marrow aspirate and/or&#xD;
             biopsy at screening, during and at the end of therapy on this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe hypersensitivity reactions to any ingredient of study treatment&#xD;
             and/or their excipients.&#xD;
&#xD;
          2. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon,&#xD;
             kinase inhibitors or other targeted small molecules, and toxin immunoconjugates) or&#xD;
             any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          3. High-risk patients for Tumor Lysis Syndrome according to Cairo et al 2010 criteria or&#xD;
             local guidelines.&#xD;
&#xD;
          4. Impaired cardiac function or clinically significant cardiac disease, or history or&#xD;
             current diagnosis of ECG abnormalities indicating significant risk of safety including&#xD;
             any of the following:&#xD;
&#xD;
               1. Concomitant clinically significant cardiac arrhythmias, e.g. sustained&#xD;
                  ventricular tachycardia, and clinically significant second- or third-degree AV&#xD;
                  block without a pacemaker&#xD;
&#xD;
               2. Any history of clinical important abnormalities in rhythm, conduction or&#xD;
                  morphology of resting ECG e.g. complete left bundle branch block, third degree&#xD;
                  heart block&#xD;
&#xD;
               3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events such as heart failure, significant hypokalemia, congenital long QT&#xD;
                  syndrome, family history of long QT syndrome or unexplained sudden death under 40&#xD;
                  years of age&#xD;
&#xD;
               4. Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment&#xD;
&#xD;
               5. Use of agents known to prolong the QT interval unless it can be permanently&#xD;
                  discontinued for the duration of study.&#xD;
&#xD;
               6. Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline&#xD;
                  (left ventricular ejection fraction [LVEF] &lt;50%)&#xD;
&#xD;
               7. Symptomatic congestive heart failure (New York Heart Association ≥ 3)&#xD;
&#xD;
               8. Findings observed in the baseline cardiac MRI that might reflect an increased&#xD;
                  risk for cardiac adverse events.&#xD;
&#xD;
          5. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M-CSF),&#xD;
             thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior to start of&#xD;
             study treatment. If thrombopoietin mimetics or erythroid stimulating agents were&#xD;
             initiated more than 2 weeks prior to the first dose of study treatment and the patient&#xD;
             is on a stable dose, they can be maintained.&#xD;
&#xD;
          6. For AML patients: Peripheral blast counts &gt; 25,000 blasts / mm3. Patients can receive&#xD;
             hydroxyurea to control the peripheral blast counts as long as hydroxyurea can be&#xD;
             stopped at least 24 hours prior to obtaining PD biomarkers at screening/baseline.&#xD;
             Hydroxyurea can be restarted after sampling if clinically indicated to control blasts&#xD;
             prior to the start of study treatment markers.&#xD;
&#xD;
          7. For patients with R/R NHL and R/R MM:&#xD;
&#xD;
               -  Absolute Neutrophil count &lt; 1.0 x 109/L&#xD;
&#xD;
               -  Platelets count &lt; 50 x 109/ L&#xD;
&#xD;
               -  Hemoglobin &lt; 8 g/dl&#xD;
&#xD;
          8. Autologous stem cell transplant within 3 months before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          9. Patients who have undergone a prior allogeneic stem cell transplant before the first&#xD;
             dose of study treatment.&#xD;
&#xD;
         10. History of or current interstitial lung disease or pneumonitis grade ≥ 2.&#xD;
&#xD;
         11. Impaired hepatic and renal function defined as:&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 1.5 x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &gt;1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin)&#xD;
&#xD;
               -  Creatinine clearance &lt;50 mL/min (calculated using Cockroft-Gault formula, or&#xD;
                  measured).&#xD;
&#xD;
         12. Lipase &gt;1.5 x ULN or serum amylase &gt;1.5 x ULN and no history of pancreatitis.&#xD;
&#xD;
         13. Increased cardiac troponin above the manufacturer's 99th percentile upper reference&#xD;
             limit for local assay at screening&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto Gun</city>
        <state>Shizuoka</state>
        <zip>411 8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib, BHLRM, VOB560, MIK665, NHL, AML, MM, Bcl2, Mcl1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

